Tough business climate roils IMS

IMS Health said it intends to lay off 10% of its workforce, or as many as 760 employees worldwide. The firm will take a 2007 Q4 charge of $86-$90 million to account for the terminations.

To be completed by year's end, IMS said the layoffs are designed to help survive a tough business climate. Last year many of its potential clients announced layoffs, including Pfizer, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb and Amgen. Meanwhile, IMS saw moderating revenue growth and pressure on operating margins.

In an SEC filing, IMS said its restructuring would impact 1,050 employees. (The firm may add back some new positions in higher growth markets.) Those who do statistical and analytical work, as well as consultants, will be affected, as well as marketing, finance and administration.

IMS, which operates in more than 100 countries with about 7,600 employees worldwide, had 2006 revenue of $2 billion. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.